Suppr超能文献

将三唑支架作为针对2N4R Tau和α-突触核蛋白聚集体的强效抗纤维化剂进行研究。

Inspecting the Triazole Scaffold as Powerful Antifibril Agents against 2N4R Tau and α-Synuclein Aggregates.

作者信息

Elbatrawy Ahmed A, Ademoye Taiwo A, Alnakhala Heba, Tripathi Arati, Zhu Xiongwei, Plascencia-Villa Germán, Perry George, Dettmer Ulf, Fortin Jessica S

机构信息

Department of Basic Medical Sciences, College of Veterinary Medicine, Purdue University, West Lafayette, Indiana 47907, United States.

Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts 02115, United States.

出版信息

ACS Omega. 2025 Feb 12;10(7):6721-6734. doi: 10.1021/acsomega.4c08385. eCollection 2025 Feb 25.

Abstract

Alzheimer's (AD) and Parkinson's (PD) disease are neurodegenerative disorders that are considered to be a significant global health challenge due to their increasing prevalence and profound impact on both individuals and society. These disorders are characterized by the progressive loss of neuronal function, leading to cognitive and motor impairments. A key pathological feature of AD and PD is the abnormal accumulation of misfolded proteins within the brain. In AD, amyloid-beta aggregates into plaques, while tau proteins form neurofibrillary tangles (NFTs). Parkinson's disease, on the other hand, is marked by the accumulation of α-synuclein (α-syn) in the form of Lewy bodies (LBs). These protein aggregates are involved in neuronal dysfunction and neurodegeneration, contributing to disease progression. Research efforts are increasingly focused on identifying small molecules that can simultaneously target multiple pathological processes, offering the potential to not only alleviate symptoms but also modify the progression of neurodegeneration. Herein, a novel group of triazole-based compounds was designed and synthesized to curtail the aggregation of α-syn and tau proteins, which are closely linked to the physiopathology of PD and AD, respectively. A thioflavin T (ThT) fluorescence assay was used to measure fibril formation and assess the antiaggregation effects of various compounds. To further validate these findings, transmission electron microscopy (TEM) was employed as a direct method to visualize the impact of these compounds on fibril morphology. Inhibition of oligomer formation was evaluated using photoinduced cross-linking of unmodified proteins (PICUP), enabling the detection of early protein aggregation events. During fibril formation assays, three compounds (, , ) demonstrated superior inhibitory activity as assessed by ThT fluorescence and TEM imaging. Subsequent evaluations, which included tests for antioligomer, anti-inclusion, and disaggregation effects identified compound as the most promising candidate overall.

摘要

阿尔茨海默病(AD)和帕金森病(PD)是神经退行性疾病,由于其患病率不断上升以及对个人和社会的深远影响,被视为一项重大的全球健康挑战。这些疾病的特征是神经元功能逐渐丧失,导致认知和运动障碍。AD和PD的一个关键病理特征是大脑中错误折叠蛋白的异常积累。在AD中,β-淀粉样蛋白聚集成斑块,而tau蛋白形成神经原纤维缠结(NFTs)。另一方面,帕金森病的特征是α-突触核蛋白(α-syn)以路易小体(LBs)的形式积累。这些蛋白质聚集体与神经元功能障碍和神经退行性变有关,促进疾病进展。研究工作越来越集中在识别能够同时针对多种病理过程的小分子上,这不仅有可能缓解症状,还可能改变神经退行性变的进程。在此,设计并合成了一组新型的基于三唑的化合物,以抑制分别与PD和AD的生理病理学密切相关的α-syn和tau蛋白的聚集。使用硫黄素T(ThT)荧光测定法来测量纤维形成并评估各种化合物的抗聚集作用。为了进一步验证这些发现,采用透射电子显微镜(TEM)作为直接方法来观察这些化合物对纤维形态的影响。使用未修饰蛋白质的光诱导交联(PICUP)评估寡聚体形成的抑制作用,从而能够检测早期蛋白质聚集事件。在纤维形成测定过程中,通过ThT荧光和TEM成像评估,三种化合物(,,)表现出优异的抑制活性。随后的评估,包括抗寡聚体、抗包涵体和解聚作用测试,确定化合物为总体上最有前途的候选物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a318/11866179/d8c84e4e5834/ao4c08385_0001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验